ICH E6(R3) Clinical Trial Compliance: Is Your CTMS Ready for the Biggest Regulatory Shift in a Decade?

ICH E6(R3) is now in force across the United States (via FDA finalization in September 2025), Canada (Health Canada as of April 2026), Europe (July 2025), and the United Kingdom (MHRA as of April 2026), fundamentally changing how clinical trials are designed, managed, monitored, and audited. Organizations must now demonstrate Quality-by-Design (QbD), risk-based oversight, validated computerized systems, and stronger data integrity than ever before.

At myLaminin, we were well positioned to respond to this shift. Our Clinical Trial Operations (CTOps) and Clinical Trials Management System (CTMS) modules were built specifically for these new needs. Crucially, they weren’t built in a vacuum. Our platform is the direct result of an extensive, rigorous co-design process alongside several elite clinical research coordinators who actively manage more than 30 complex, multi-site trials across the demanding fields of cardiac and cancer research.

When you design a platform to survive the operational pressures of oncology and cardiology, you build a platform that can handle anything. Here is how myLaminin delivers on that promise across every pillar of the study ecosystem.

1. The Clinical Trial Team & Principal Investigator (PI) Perspective: Reducing Burden, Enhancing Oversight

For PIs and trial coordinators, the primary enemy is administrative friction. ICH E6(R3) places explicit responsibility on the PI for the oversight of trial conduct and data integrity at their site - responsibility that can’t be delegated. Our CTMS module turns that responsibility from a liability into a streamlined, and auditable routine.

• Real-Time Visibility & Oversight: Instead of digging through disconnected spreadsheets, PIs have a consolidated display of enrollment metrics, protocol deviations, and safety event tracking across all active sites.

• Operational Fluidity: Built with direct input from coordinators handling fast-moving cardiac trials, our powerful Clinical Trial Protocol Definition and Participant Tracking workflow engine ensure that critical data collection, patient updates, eligibility verifications, and randomized allocations happen seamlessly, keeping the focus entirely on patient safety and data quality.

• Proportional Effort: By facilitating the identification of "critical-to-quality" factors, their Quality Tolerance Limits (QTLs) and required notifications, the system seamlessly alerts the team to high-risk protocol deviations while eliminating the white noise of low-impact administrative discrepancies.

2. The Administrative Perspective: Institutional Scalability & Ultimate Security

From an institutional and administrative standpoint, software must do two things: scale seamlessly across multi-site or global teams, and protect the organization from liability.

myLaminin serves as a solid foundation for enterprise-level operations.

myLaminin eliminates cross-border technological roadblocks while ensuring total structural security through an industry-leading compliance matrix:

Functional Area	Embedded Compliance Standards
Data Integrity & Attributability	Full 21 CFR Part 11 compliance with cryptographic eSignatures and comprehensive, immutable system audit trails.
Security & Operational Trust	Fully vetted with a verified SOC2 Type II certification.
Global Privacy & Data Sovereignty	Total alignment with GDPR (EU), HIPAA (US), and Canadian provincial/federal acts (PHIPA and PIPEDA).
Global Accessibility	Fully Multi-Lingual and strictly compliant with WCAG 2.1 accessibility standards, ensuring equity for both global staff and diverse patient registries.

Administrators gain an environment where data is siloed appropriately by region or protocol, yet global data standardization remains unified across the entire enterprise. More importantly, because myLaminin is a fully integrated Clinical Research Data Management (RDM) platform, it can deliver the Real-Time Clinical Trials (RTCTs) that the FDA is moving towards. As each new participant is enrolled, or as a reportable event is registered in the platform, myLaminin has the analytical and reporting capabilities to deliver real-time dashboard report updates and/or notifications to different stakeholders as required.

3. The Compliance & Monitor Perspective: Audit-Readiness by Design

The new ICH E6(R3) rules place severe scrutiny on computerized systems, requiring validation evidence that a platform is "fit for purpose". For clinical monitors and quality assurance teams, myLaminin shifts monitoring from a reactive "catch-up" or “over the shoulder” exercise to a proactive, centralized workflow.

• End-to-End Traceability: Every data point adheres strictly to the modernized ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, and Complete). Centralized monitors can trace any piece of source data back to its exact origin, timestamp, and the user who initiated it.

• Risk-Based Quality Management (RBQM): The myLaminin CTMS doesn't just store data—it evaluates it. The system allows compliance teams to define data tolerance limits from the outset on any data item captured through our integrated data collection forms. If a multi-site oncology trial hits an unexpected trend in protocol deviations, the system automatically flags it for targeted, remote monitoring before it jeopardizes the study.

• Frictionless Inspection Preparedness: When a regulatory auditor or sponsor monitor requests access, myLaminin provides clean, scoped read-only compliance views. There is no scrambling to compile training logs, delegation logs, or system validation records, they are permanently linked to the trial and easily accessible through read-only role-based access control of the monitor profile.

Built For What Matters Most

The ultimate validation of myLaminin doesn't come from a regulatory or functional checklist; it comes from the clinical research coordinators. It comes from the peace of mind experienced by a coordinator managing 30+ intervention and non-intervention trials, knowing that their data governance is flawless. It comes from the PI who can confidently sign off on an electronic record knowing it meets global scrutiny.

We co-designed this platform with some meticulous researchers because we believe that software should never be a bottleneck to medical innovation. As ICH E6(R3) reshapes this industry, myLaminin is focused on ensuring trials remain safe, secure, compliant, and ahead of the curve.

Note: We frequently adapt and enhance specific features within these modules. If you would like to see how we integrated electronic data capture (EDC), clinical trial protocol definition and participant tracking with the operational eTMF, delegation logs, and automated payment schedules and invoicing, please reach out.

__________________________________

Ash Bassili (article author) is the CEO of myLaminin, a compliance-first Clinical and Research Data Management platform for regulated cross-institution research. He holds a BSc Hons Life Sciences from Queen’s University, a MSc in Information Technology from Johns Hopkins University, and a Certificate in Blockchain Technologies from MIT Sloan School of Management.